Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Convertible Debt: 2014-2021

Historic Convertible Debt for Ligand Pharmaceuticals (LGND) over the last 6 years, with Dec 2021 value amounting to $320.7 million.

  • Ligand Pharmaceuticals' Convertible Debt fell 49.89% to $176.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $176.5 million, marking a year-over-year decrease of 49.89%. This contributed to the annual value of $320.7 million for FY2021, which is 27.49% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Convertible Debt of $320.7 million as of FY2021, which was down 27.49% from $442.3 million recorded in FY2020.
  • Ligand Pharmaceuticals' Convertible Debt's 5-year high stood at $639.0 million during FY2019, with a 5-year trough of $320.7 million in FY2021.
  • For the 3-year period, Ligand Pharmaceuticals' Convertible Debt averaged around $467.3 million, with its median value being $442.3 million (2020).
  • Its Convertible Debt has fluctuated over the past 5 years, first grew by 4.77% in 2019, then crashed by 30.78% in 2020.
  • Yearly analysis of 4 years shows Ligand Pharmaceuticals' Convertible Debt stood at $609.9 million in 2018, then rose by 4.77% to $639.0 million in 2019, then tumbled by 30.78% to $442.3 million in 2020, then declined by 27.49% to $320.7 million in 2021.